Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update

(2018) Morgan Rouprêt et al.   EUROPEAN UROLOGY

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients

(2018) Mihai Dorin Vartolomei et al.   WORLD JOURNAL OF UROLOGY

Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy

(2018) Hui-Shan Huang et al.   Scientific Reports

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

(2018) A. Gordon Robertson et al.   CELL

Programmed death ligand‐1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder

(2018) Bo Wang et al.   CANCER SCIENCE

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

(2017) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Neutrophils in cancer: prognostic role and therapeutic strategies

(2017) Alberto Ocana et al.   Molecular Cancer

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma

(2017) Dongxian Jiang et al.   Scientific Reports

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma

(2016) Elizabeth D Thompson et al.   GUT

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder

(2016) Alexander S. Baras et al.   OncoImmunology

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients

(2015) H. Kakavand et al.   CLINICAL CANCER RESEARCH

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder

(2015) Bo Wang et al.   JOURNAL OF UROLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

(2014) Arnoud J. Templeton et al.   JNCI-Journal of the National Cancer Institute

Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions

(2013) Nobuyuki Tanaka et al.   BJU INTERNATIONAL

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy

(2013) Matthew D. Galsky et al.   CANCER

Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder

(2013) E. Xylinas et al.   EJSO

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines

(2011) Arnulf Stenzl et al.   EUROPEAN UROLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer

(2010) Takao Kamai et al.   BMC CANCER

Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy

(2010) Brian R. Lane et al.   CANCER

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Changes in Renal Function Following Nephroureterectomy May Affect the Use of Perioperative Chemotherapy

(2010) Matthew G. Kaag et al.   EUROPEAN UROLOGY

Regulatory T Cells and Immune Tolerance

(2008) Shimon Sakaguchi et al.   CELL

T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival

(2008) S. A. Boorjian et al.   CLINICAL CANCER RESEARCH